Failure of Dupilimab with Severe Prurigo Nodularis That Responded Well to Abrocitinib

Abstract

Get full access to this article

View all access options for this article.

References

Labib

, Ju

, Vander Does

, et al. Immunotargets and therapy for prurigo nodularis. Immunotargets Ther, 2022; 11:11–21. doi:10.2147/ITT.S316602.

Yosipovitch

, Mollanazar

, Stander

, et al. Dupilumab significantly improves itch and skin lesions in patients with prurigo nodularis: results from a 2nd phase 3 trial (LIBERTY-PN PRIME) [oral presentation]. EADV Congress. 2022, Milan, Italy.

Agrawal

, Sardana

, Mathachan

, et al. A prospective study examining the expression of STAT 1, 3, 6 in prurigo nodularis lesions with its immunopathogenic and therapeutic implications. J Cosmet Dermatol, 2022; 21(9):4009–4015. doi:10.1111/jocd.14709.

, Labib

, Vander Does

, et al. Topical Janus kinase-signal transducers and activators of transcription inhibitor tofacitinib is effective in reducing nonatopic dermatitis chronic itch: a case series. J Am Acad Dermatol, 2022; 87(2):400–403. doi:10.1016/j.jaad.2022.03.012.

Molloy

, Kearney

, Byrne

, et al. Successful treatment of recalcitrant nodular prurigo with tofacitinib. Clin Exp Dermatol, 2020; 45(7):918–920. doi:10.1111/ced.14320.